How Various Breast Cancer Screening Guidelines Compare

Slideshow

In this slideshow, various clinical guidelines on breast cancer screening are summarized, including the ACP's recent recommendations that have come under some scrutiny.

According to the National Cancer Institute, breast cancer is the second most common cause of cancer-related death among women in the United States. Screening can help to find cancer at an early stage, when treatment is most effective and cure is more likely. Key professional organizations have published various clinical guidelines regarding when and how often to screen women at average and high-risk for breast cancer. However, their recommendations are not always concordant. The American College of Physicians (ACP) recently released new screening guidelines for average-risk women that have come under some scrutiny. This slideshow highlights the ACP’s updated guidance as well as several other breast cancer screening recommendations from key healthcare organizations and societies.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.